📣 VC round data is live. Check it out!
- Public Comps
- DexCom
DexCom Valuation Multiples
Discover revenue and EBITDA valuation multiples for DexCom and similar public comparables like Philips, GE HealthCare, Mindray, Halma and more.
DexCom Overview
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Founded
1999
HQ

Employees
11.1K
Website
Financials (LTM)
EV
$25B
Valuation Multiples
Start free trialDexCom Financials
DexCom reported last 12-month revenue of $5B and EBITDA of $1B.
In the same LTM period, DexCom generated $3B in gross profit, $1B in EBITDA, and $894M in net income.
Revenue (LTM)
DexCom P&L
In the most recent fiscal year, DexCom reported revenue of $5B and EBITDA of $1B.
DexCom is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 29%, and net margin of 18%.
Financial data powered by Morningstar, Inc.
DexCom Stock Performance
DexCom has current market cap of $26B, and enterprise value of $25B.
Market Cap Evolution
DexCom's stock price is $66.95.
DexCom share price increased by 12.4% in the last 30 days, and decreased by 22.0% in the last year.
DexCom has an EPS (earnings per share) of $2.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25B | $26B | 2.9% | 12.4% | -8.8% | -22.0% | $2.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDexCom Valuation Multiples
DexCom trades at 5.1x EV/Revenue multiple, and 17.0x EV/EBITDA.
EV / Revenue (LTM)
DexCom Financial Valuation Multiples
As of May 20, 2026, DexCom has market cap of $26B and EV of $25B.
DexCom has a P/E ratio of 28.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DexCom Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


DexCom Margins & Growth Rates
DexCom grew revenue by 12% and EBITDA by 20% in the last fiscal year.
In the most recent fiscal year, DexCom reported gross margin of 60%, EBITDA margin of 29%, and net margin of 18%.
DexCom Margins
DexCom Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
DexCom Operational KPIs
DexCom's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
DexCom's Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DexCom's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
DexCom Competitors
DexCom competitors include Philips, GE HealthCare, Mindray, Halma, ResMed, Illumina, Mettler Toledo, Steris, Agilent and Alcon.
Most DexCom public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.5x | 1.5x | 9.0x | 8.9x | |||
| 1.8x | 1.7x | 9.6x | 9.8x | |||
| 5.2x | 5.1x | 15.2x | 15.6x | |||
| 7.7x | 6.8x | 31.8x | 27.4x | |||
| 5.6x | 5.2x | 15.1x | 13.4x | |||
| 5.3x | 5.2x | 15.7x | 18.3x | |||
| 5.8x | 5.7x | 18.6x | 18.2x | |||
| 4.1x | 3.8x | 16.6x | 13.2x | |||
This data is available for Pro users. Sign up to see all DexCom competitors and their valuation data. Start Free Trial | ||||||
DexCom M&A Activity
DexCom has acquired 2 companies to date.
Last acquisition by DexCom was on August 22nd 2018. DexCom acquired TypeZero Technologies for $11M (EV/Revenue multiple of ).
Latest Acquisitions by DexCom
| Description | TypeZero Technologies is a Charlottesville, Virginia-based medical device company offering the inControl automated insulin delivery system for type 1 diabetes management. Acquired by United Therapeutics in 2018 after pivotal trials demonstrating improved time-in-range metrics, its FDA-cleared platform integrates continuous glucose monitors with insulin pumps for closed-loop control. TypeZero collaborates with Dexcom and Tandem Diabetes Care to simplify therapy for over 1.25 million U.S. patients. | Nintamed is a medical device distributor operating in Germany, Switzerland, and Austria. Munich-headquartered, it supplies endoscopy equipment, surgical robots, and diagnostic imaging systems from brands like Karl Storz and Olympus. The company maintains certified warehouses in Zurich and Vienna, offering training academies and maintenance contracts. Nintamed serves hospitals and clinics with just-in-time delivery and CE-marked inventory. |
| HQ Country | ||
| HQ City | Charlottesville, VA | Mainz |
| Deal Date | 22 Aug 2018 | 2 May 2016 |
| Valuation | $11M | $7M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all DexCom acquisitions and their M&A valuation multiples. Start Free Trial | ||
DexCom Investment Activity
DexCom has invested in 4 companies to date.
Latest investment by DexCom was on November 19th 2024. DexCom invested in Oura in their $200M Series D round (EV/Revenue multiple of ).
Latest Investments by DexCom
| Description | Oura is a Helsinki-headquartered company founded in 2013 that manufactures the Oura Ring Gen3, a finger-worn sensor tracking heart rate, blood oxygen, temperature, and sleep stages. The companion app delivers readiness, activity, and recovery scores used by professional athletes and over 10 million app downloads worldwide. Available in the US, Europe, and Asia through direct sales and retailers like Best Buy. | Phenomix Sciences is a New York-headquartered biotechnology firm specializing in pharmacogenomics for chronic disease management including diabetes and cardiovascular conditions. Its testing panels analyze metabolomics and genetic markers to tailor medications reducing adverse effects. Founded in 2017, the company partners with clinics nationwide offering CLIA-certified lab services processed in under 48 hours. | Current Health is a London-headquartered remote patient monitoring platform enabling virtual care delivery for hospitals and health systems. The company provides wearable devices, AI analytics, and clinician dashboards to track vital signs like heart rate, oxygen levels, and activity in chronic disease patients. Acquired by Best Buy Health in 2021, it serves providers across the United States and United Kingdom, including partnerships with the National Health Service and major insurers. Deployed in over 100 hospitals, the platform supports post-discharge management and telehealth integrations. | Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet. |
| HQ Country | ||||
| HQ City | Oulu | Rochester, MN | Boston, MA | — |
| Deal Date | 19 Nov 2024 | 6 May 2024 | 17 Jun 2020 | 8 Jan 2019 |
| Round | Series D | Series A | Series A | Series B |
| Raised | $200M | $6M | $4M | $63M |
| Investors | Andreessen Horowitz; DexCom; Fidelity; Temasek Holdings | DexCom; Health2047; Labcorp | DexCom; Legal & General; MMC Ventures; Par Equity | ArrowMark Partners; DexCom; Eventide; LifeSci Venture Partners; RTW Investments; Zealand Pharma |
| Valuation | $5B | undisclosed | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all DexCom investments and their VC round multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DexCom
| When was DexCom founded? | DexCom was founded in 1999. |
| Where is DexCom headquartered? | DexCom is headquartered in United States. |
| How many employees does DexCom have? | As of today, DexCom has over 11K employees. |
| Who is the CEO of DexCom? | DexCom's CEO is Jacob S. Leach. |
| Is DexCom publicly listed? | Yes, DexCom is a public company listed on Nasdaq. |
| What is the stock symbol of DexCom? | DexCom trades under DXCM ticker. |
| When did DexCom go public? | DexCom went public in 2005. |
| Who are competitors of DexCom? | DexCom main competitors include Philips, GE HealthCare, Mindray, Halma, ResMed, Illumina, Mettler Toledo, Steris, Agilent, Alcon. |
| What is the current market cap of DexCom? | DexCom's current market cap is $26B. |
| What is the current revenue of DexCom? | DexCom's last 12 months revenue is $5B. |
| What is the current revenue growth of DexCom? | DexCom revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of DexCom? | Current revenue multiple of DexCom is 5.1x. |
| Is DexCom profitable? | Yes, DexCom is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DexCom? | DexCom's last 12 months EBITDA is $1B. |
| What is DexCom's EBITDA margin? | DexCom's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of DexCom? | Current EBITDA multiple of DexCom is 17.0x. |
| What is the current FCF of DexCom? | DexCom's last 12 months FCF is $1B. |
| What is DexCom's FCF margin? | DexCom's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of DexCom? | Current FCF multiple of DexCom is 19.3x. |
| How many companies DexCom has acquired to date? | As of May 2026, DexCom has acquired 2 companies. |
| What was the largest acquisition by DexCom? | $11M acquisition of TypeZero Technologies on 22nd August 2018 was the largest M&A DexCom has done to date. |
| What companies DexCom acquired? | DexCom acquired TypeZero Technologies and Nintamed. |
| In how many companies DexCom has invested to date? | As of May 2026, DexCom has invested in 4 companies. |
| What was the last DexCom investment? | On 19th November 2024 DexCom invested in Oura, participating in a $200M Series D round at $5B valuation, alongside Andreessen Horowitz, Fidelity, and Temasek Holdings. |
| In what companies DexCom invested in? | DexCom invested in Oura, Beta Bionics, Phenomix Sciences, and Current Health. |
See public comps similar to DexCom
Lists including DexCom
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


